Franklin FTSE Switzerland ETF (FLSW)

The Franklin FTSE Switzerland ETF brings U.S. investors exposure to Switzerland’s public equity markets. Traded on the NYSE under the ticker FLSW, it tracks the FTSE Switzerland Index, which holds the country’s largest publicly traded companies. Switzerland’s economy is concentrated in a handful of globally dominant sectors—pharmaceuticals, banking, consumer staples, and industrial goods—and FLSW’s portfolio reflects that composition.

For investors seeking a developed-market, non-U.S., non-European-Union hedge, or those interested in Switzerland’s idiosyncratic strengths in pharmaceuticals and wealth management, the fund offers a clean vehicle. It avoids the currency and custody complications that come with buying Swiss shares directly on the SIX exchange in Zurich.

The pharmaceutical anchor

The single largest sector in FLSW is pharmaceuticals and life sciences. Two of the world’s largest drug makers—Roche and Novartis—are Swiss-domiciled and typically represent the bulk of the index’s weight. Both are truly global companies: they sell far more drugs outside Switzerland than within it, and their profitability depends on the health of global healthcare spending, the pace of new drug approvals, and patent protection for their bestsellers. Owning FLSW is, in large part, owning a concentrated bet on global pharmaceutical demand and on the ability of these two firms to innovate and extend their franchises.

Roche, which is majority-owned by a long-standing family shareholder and does not trade on a primary U.S. exchange, is accessible to U.S. investors almost entirely through vehicles like FLSW or American Depository Receipts. For investors who believe in the durability of premium pharmaceutical companies and want that exposure without holding single-stock risk, the fund provides it. But investors should be aware that they are also taking geopolitical risk specific to Switzerland—a politically stable, non-EU country with its own tax and regulatory regime around drug pricing and pharmaceutical innovation.

Banking and insurance

Switzerland’s second major sector concentration is financial services—banking, insurance, and wealth management. UBS and Credit Suisse were historically the dominant Swiss banks and core holdings in the index, though the financial crisis, subsequent regulatory changes, and Credit Suisse’s 2023 emergency acquisition have reshaped this landscape. The surviving domestic banks manage enormous amounts of global wealth and generate profit from managing assets for international clients. Asset management fees, which flow to banks in proportion to the assets they oversee, are a form of recurring revenue—less exposed to interest rates and more stable than traditional lending.

This banking exposure means FLSW has meaningful sensitivity to global monetary policy, to the health of ultra-high-net-worth clients (who pull back during recessions), and to regulatory pressures around banking secrecy and international tax compliance that have borne heavily on Switzerland.

Consumer goods and industrial

Nestlé, one of the world’s largest food and beverages companies, is a substantial holding in the index and another globally diversified anchor that happens to be domiciled in Switzerland. The company derives revenue from coffee, pet food, healthcare nutrition, bottled water, and countless other consumer staples sold across the globe. Like the pharma holdings, Nestlé’s Swiss domicile is almost incidental to its business; it is a global consumer company that happens to be owned and traded through a Swiss entity.

Alongside pharma, banking, and consumer goods sits a long tail of Swiss industrial, luxury, and engineering companies—watchmakers, machinery makers, and specialty manufacturers. These add diversification within the fund but remain dwarfed by the giants.

Currency and hedging

FLSW is denominated in U.S. dollars, and the fund implements currency hedging to the dollar. This isolates returns to movements in the Swiss franc relative to the dollar. Without this hedge, an investor would face both equity risk (Swiss stocks rising or falling) and currency risk (the franc strengthening or weakening). With hedging, the sole bet is on the Swiss equities themselves. That is usually what U.S. investors want when they buy a foreign-country ETF—they are expressing a view on that country’s stocks, not making a currency bet.

The Swiss franc has historically been a “safe haven” currency that appreciates during global stress, while Swiss equities have often been under pressure during the same periods. The hedging structure isolates those two effects so that FLSW’s returns depend only on the equity market performance, not on whether international investors are fleeing into francs.

Concentration and liquidity

FLSW is a focused portfolio—roughly forty holdings, heavily weighted toward the pharmaceutical and financial giants. This is not a broad, diversified market like the U.S. or European indices. Investors are accepting higher concentration in exchange for purer exposure to the specific sectors and companies that dominate Switzerland’s capital markets. That concentration means the fund’s returns can diverge sharply from broader emerging-market or international developed-market indices.

Liquidity in the fund itself is typically good because the underlying Swiss shares trade on the SIX exchange with ample daily volume. The ETF trades on the NYSE, where it usually has tight bid-ask spreads. However, investors should consult the fund’s fact sheet for current holdings and concentrations, as the weight of any single company can shift with market movements.

Researching Swiss equity markets

Investors interested in FLSW should begin with the fund’s prospectus and fact sheet, which show the current top holdings and sector breakdown. Reading recent annual reports from Roche, Novartis, and Nestlé is instructive because those three companies often represent a large plurality of the fund’s assets. Understanding the competitive landscape in global pharmaceuticals, the regulatory environment around drug pricing, and the long-term prospects for those companies’ pipelines is essential to understanding where FLSW’s returns will come from.

The broader question is whether Swiss domiciliation offers investors anything beyond geographic diversification—whether the structural advantages of Switzerland as a business location (stability, legal infrastructure, historical banking strength) will continue to support the outperformance of these globally dominant firms, or whether their fortunes will track the world markets regardless of where they are headquartered.